Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?

Longer Term Data Ready Soon

 
• By Andrew McConaghie

The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.

Older person vaccine
Both vaccines look set for approval in time for the fall/winter RSV season, but broad uptake will depend on long-term data. • Source: Shutterstock

More from Business

More from Scrip